Huadong Medicine Co Ltd

Huadong Medicine Co Ltd maintains a strong liquidity position, with a current ratio of 1.53, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests it is in a stable position relative to its peers, though it is not immune to short-term cash flow pressures. Free cash flow for the period was 947 million CNY, which is a positive sign for reinvestment or shareholder returns. Profitability metrics show the company is performing well relative to industry norms. Return on equity (ROE) of 15.23% and return on assets (ROA) of 9.27% are both above the median for the Pharmaceuticals industry, indicating efficient use of equity and assets to generate profit. Gross profit of 13.9 billion CNY and operating income of 4.32 billion CNY further support the company's strong profitability. The company's revenue is concentrated in its domestic market, with no disclosed international segments. This concentration may expose the company to regulatory and economic risks specific to China, though it also allows for focused operations and potentially higher margins. Looking ahead, the company is expected to maintain a stable growth trajectory. Analysts project a mean price target of 47.63 CNY, with a median of 46.55 CNY, and a generally positive outlook with 7 strong-buy and 5 buy recommendations. Revenue growth is expected to remain steady, supported by the company's strong cash flow and low dilution risk. Risk factors include moderate liquidity risk, as the company has negative net cash after subtracting total debt. However, the debt-to-equity ratio of 0.13 suggests a conservative capital structure with limited leverage. There is currently no indication of near-term dilution pressure, with low dilution risk and no recent share issuance activity reported. Recent events include strong analyst sentiment, with a mean recommendation of 1.71 (on a 1–5 scale, where 1 is strong buy) and a broad range of price targets from 39.00 to 57.00 CNY. No recent filings or transcripts indicate material changes in strategy or operations, suggesting the company is maintaining its current course.